

Curriculum Vitae

Stefan Endres Professor, Dr. med., M.D., B.A.
d.o.b. June 17th, 1957, in Augsburg, Germany

University Education

- 1984 M.D. degree with *magna cum laude*, Ludwig-Maximilians-Universität, Munich, Germany
- 1983 State Medical Boards, Munich
- 1982 Core clinical clerkship Internal Medicine at Beth Israel Hospital, Harvard Medical School, Boston
- 1979 Bachelor of Arts degree with *magna cum laude*, Department of Biochemistry and Immunology, Harvard University
- 1977 - 1979 Two years study at Harvard University, Cambridge, Massachusetts
- 1975 Entering Medical School at Ludwig-Maximilians-Universität, Munich
- 1974 Second Prize in German Federal Mathematics Competition (Bundeswettbewerb Mathematik)
- 1967 - 1975 Secondary School Gymnasium bei St. Anna (humanistic, modern languages), Augsburg; skipping grade 10.

Scientific Career

- 2018 - Member of the Wissenschaftlichen Beirats der Bundesärztekammer (Scientific Advisory Board of the German Medical Association, 2018 bis 2021)
- 2017 - Appointment to the Advisory Committee for BioM Biotech Cluster Development Gesellschaft by Staatsministerin Isle Aigner, Bayerisches Wirtschaftsministerium
- 2016 - German Cancer Consortium (DKTK); Member of local steering committee; partner site Munich; Member of the Ethics Committee of the Medical Faculty
- 2015 - 2019 Speaker of newly established Marie-Sklodowska-Curie training network "Immutrain: Immunotherapy of Cancer", funded by Horizon 2020 (2015 to 2019)
- 2014 - Speaker of International Doctoral Program "i-Target: Immuntargeting of Cancer", funded by Elite Network of Bavaria (2014 to 2018; second funding period approved 2018 to 2022)
- 2013 - Scientific advisor for the Paul Martini-Stiftung
- 2013 - Member of the Scientific Board (Wissenschaftskommission) of the Else Kröner Fresenius-Stiftung; since 2015 Deputy Chairman: since 2017 Chairman
- 2012 - 2019 Area coordinator (Area D: Protein nucleic acid interactions) and PI, excellence cluster Center of Integrated Protein Science (CIPS-M), 2012 to 2018
- 2012 Member of search committee for chief of medicine (Ärztlicher Direktor) of Klinikum der Ludwig-Maximilians-Universität
- 2011 Member of Scientific Advisory Committee, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital, Harvard University, Boston
- 2011 Appointment as Visiting Professor Harvard Medical School, Division of Immunology (Laboratory Prof. von Andrian), April to August 2011
- 2011 Appointment as Jury Member for European Research Council (ERC), Selection Jury Advanced Investigator Grant, Panel Immunology and Infection
- 2009 - 2015 Spokesman of the DFG Graduate Research Centre GK 1202 "Oligonucleotides in cell biology and therapy" (renewal 3.5 million Euro funding 2010 to 2015)
- 2007 - Dean of Research, Medical Faculty, Ludwig-Maximilians-Universität; reelection for terms 2010 to 2013, 2013 to 2016, 2016 to 2019, 2019 to 2022 (2017 budget for research and education: 148 million Euro); excellence university in the German excellence initiative
- 2006 - Board of Directors (Aufsichtsrat), reelected for term 2011 to 2016, 2016 to 2021, 2021 to 2024

- 2007 - Chairman of the newly formed Research Committee of the Medical Faculty
- 2007 - 2019 Principal investigator in the excellence cluster Center of Integrated Protein Science Munich (CIPS-M)
- 2007 - 2012 LMUexcellent Research Professor as one out of eleven grantees university-wide
- 2007 - 2012 Member of the Board of the Clinical Study Center, newly established to coordinate clinical studies at the Ludwig-Maximilians-Universität
- 2006 - Board of Directors (Aufsichtsrat) of the University Hospital, Ludwig-Maximilians-Universität München (2017 annual budget: 1.005 million Euro; 9,929 employees)
- 2006 - 2016 Consultant for biotech companies designing phase II studies for immunotherapy of patients with autoimmune or infectious diseases
- 2005 - 2006 Member of the Board (Vorstand) of the University Hospital, Ludwig-Maximilians-Universität
- 2003 - Member of the Ethics Committee (Bayerische Landesärztekammer)
- 2003 - 2007 Principal Investigator of investigator-initiated phase II study with autologous dendritic cell vaccination for patients with pancreatic cancer
- 2002 - Member of the Faculty Council (Fachbereichsrat), Medical Faculty, Ludwig-Maximilians-Universität München
- 1998 - 2009 Chairman, Subcommittee on Drugs in Gastrointestinal Disease
- 1997 - 2004 Course Director teaching program of Harvard Educational Alliance
- 1997 - Member of Committee on Drug Evaluation (Arzneimittelkommission)
- 1997 - Full Professor of Clinical Pharmacology, Director, Division of Clinical Pharmacology, Ludwig-Maximilians-Universität München

Awards and Honors

- 2020 Doktor Robert Pfleger-Award of the Doktor Robert Pfleger-Foundation
- 2019 M4-Award 2019 (500.000 Euro), Pre-foundation competition of the Bavarian Ministry of Science (with Prof. S. Kobold und B. Cadhila)
- 2004 Medal of Honor of the LMU of merits in teaching within the framework of the Munich-Harvard-Educational Alliance
- 1994 Award of a scholarship abroad of the Walter-Marget-Vereinigung for Clinical Infectiology
- 1975 Second prize in the national mathematics competition of the Stifterverband for the German Science

Citation Record

Total citations: 22,059; h-index: 71 (Web of Science, July 26th, 2022)

Top-10 selected Publications

1. Hornung V, Guenther-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougères A, **Endres S**, Hartmann G. Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nature Medicine* 2005; 11:263-70. JIF 30.6
2. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, **Endres S**, Hartmann G. 5'-triphosphate RNA is the ligand for RIG-I. *Science* 2006; 314:994-997. JIF 35.3
3. Gross O, Poeck H, Bscheidt M, Dostert C, Hanneschlaeger N, **Endres S**, Tardivel A, Tschopp J, Ruland J. Syk kinase signaling couples to the Nalp3 inflammasome for anti-fungal host defense. *Nature* 2009; 459:433-6

JIF 38.6

4. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hanneschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, **Endres S**, Peschel C, Hartmann G, Hornung V, Ruland J. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production.
Nature Immunology 2010; 11:63-9
JIF 26.2
5. Bourquin C, Hotz C, Noerenberg D, Völkl A, Heidegger S, Storch B, Sandholzer N, Wurzenberger C, Anz D, **Endres S**. Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance.
Cancer Research 2011; 71:5123-3
JIF 8.7
6. Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner CG, Klein C, Bourquin C, **Endres S**. Selective bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer.
The Journal of the National Cancer Institute 2015; 107:364.
JIF 15.2
7. Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, **Endres S**, Rothenfußer S#. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107.
JIF 15.2
8. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt K, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler W, Schnurr M, Rothenfußer S, **Endres S**, Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.
Proceedings of the National Academy of Sciences 2017; 10:1073
JIF 9.6
9. Boehmer D, Formisano S, de Oliveira Mann C, Mueller S, Kluge M, Metzger P, Rohlf M, Hörth Ch, Kocheise L, Lichtenthaler S, Hopfner KP, **Endres S**, Rothenfusser S, Friedel C, Duewell P, Schnurr* M, Koenig* L.
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.
Science Immunology 2021; 61, eabe2550.
JIF 17.7
10. Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, Dantes Z, Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kurzay M, Larimer B, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Benmeharek MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö, . . . Rothenfusser S, Duewell P, Koenig L, Schnurr M, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, **Endres S**, Kobold S.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Nature Biomedical Engineering 2021; 35:2243-2257.
JIF 20.0